1. Home
  2. KMDA vs EOLS Comparison

KMDA vs EOLS Comparison

Compare KMDA & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kamada Ltd.

KMDA

Kamada Ltd.

HOLD

Current Price

$7.02

Market Cap

460.3M

Sector

Health Care

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$5.97

Market Cap

454.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMDA
EOLS
Founded
1990
2012
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
460.3M
454.4M
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
KMDA
EOLS
Price
$7.02
$5.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$14.00
$15.50
AVG Volume (30 Days)
33.0K
776.9K
Earning Date
05-13-2026
05-04-2026
Dividend Yield
3.08%
N/A
EPS Growth
N/A
1.23
EPS
N/A
N/A
Revenue
N/A
$297,176,000.00
Revenue This Year
$13.94
$13.27
Revenue Next Year
$9.84
$17.62
P/E Ratio
$24.59
N/A
Revenue Growth
N/A
11.61
52 Week Low
$6.50
$3.86
52 Week High
$9.35
$9.72

Technical Indicators

Market Signals
Indicator
KMDA
EOLS
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
KMDA
EOLS

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Share on Social Networks: